Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Pfizer/Boehringer Spiriva Clears FDA For COPD; Launch Set For Summer

  • News

Executive Summary

Pfizer/Boehringer Ingelheim's marketing plan for Spiriva will emphasize the drug's long-term efficacy compared to other COPD therapies

You may also be interested in...



UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004

UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004

UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004

UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004

Pfizer/Boehringer Spiriva Launched At 30% Discount To Advair For COPD

Pfizer and Boehringer Ingelheim are launching the chronic obstructive pulmonary disease therapy Spiriva at a 30% discount to the average wholesale price of GlaxoSmithKline's Advair

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By